Literature DB >> 16361762

Helicobacter pylori-induced apoptosis in pathogenesis of gastric carcinoma.

Shridhar Tiwari1, Ujjala Ghoshal, Uday C Ghoshal, Sadhna Dhingra, Rakesh Pandey, Manisha Singh, Archana Ayyagari, Sita Naik.   

Abstract

BACKGROUND: Despite a possible role of Helicobacter pylori in gastric carcinoma (GC), its pathogenesis is not clear. There is scanty data on apoptosis in GC in relation to H. pylori and CagA antibody. Therefore, we studied gastric epithelial apoptosis in GC and non-ulcer dyspepsia (NUD) with or without H. pylori infection, and the degree of apoptosis in relation to CagA antibody status.
METHODS: 20 patients each with GC and NUD were investigated for H. pylori using rapid urease test (RUT), IgG anti-H. pylori and anti-CagA antibodies, histology of endoscopically normal-looking mucosa for H. pylori, intestinal metaplasia (IM), and apoptosis using TUNEL assay. Positivity to one tissue-based (RUT or histology) and one serology based (anti-H. pylori or CagA IgG) test was taken as diagnostic of active H. pylori infection, and negative result in both tissue-based tests suggested its absence.
RESULTS: Patients with GC more often had anti-H. pylori IgG (16 of 20 vs. 8 of 20; p=0.02) and a trend towards higher apoptotic index (AI) (48.6 [19.2 to 71.7] vs. 41.4 [11.7 to 63.6]; p=0.06) than NUD. AI was higher in GC (66.7 [57.5 to 71.7] vs. 32.6 [19.2 to 39.8]; p<0.0001) and NUD (58.6 [50.7 to 63.6] vs. 24.4 [11.7 to 32.2]; p<0.0001) infected with H. pylori than in those without infection. AI was also higher in GC than in NUD with H. pylori infection (66.7 [57.5 to 71.7] vs. 58.6 [50.7 to 63.6]; p=0.01). Four of the 20 patients with GC and none with NUD had IM (p=ns). There was no difference in AI in relation to CagA antibody. AI positively correlated with patients' age in presence of H. pylori infection (correlation coefficient=0.5, p=0.03) but not in its absence.
CONCLUSION: Exaggerated apoptosis may play a role in H. pylori-mediated gastric diseases including carcinogenesis. AI increases with aging in patients infected with H. pylori.

Entities:  

Mesh:

Year:  2005        PMID: 16361762

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  6 in total

1.  Genetic variants in T helper cell type 1, 2 and 3 pathways and gastric cancer risk in a Polish population.

Authors:  Rajeev Mahajan; Emad M El-Omar; Jolanta Lissowska; Paolo Grillo; Charles S Rabkin; Andrea Baccarelli; Meredith Yeager; Leslie H Sobin; Witold Zatonski; Stephen J Channock; Wong-Ho Chow; Lifang Hou
Journal:  Jpn J Clin Oncol       Date:  2008-08-07       Impact factor: 3.019

2.  The 3'-to-5' exoribonuclease (encoded by HP1248) of Helicobacter pylori regulates motility and apoptosis-inducing genes.

Authors:  Ming-Yang Tsao; Tzu-Lung Lin; Pei-Fang Hsieh; Jin-Town Wang
Journal:  J Bacteriol       Date:  2009-02-13       Impact factor: 3.490

Review 3.  Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma.

Authors:  Kartar Singh; Uday C Ghoshal
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

4.  Serum prolidase activity, oxidant and antioxidant status in nonulcer dyspepsia and healthy volunteers.

Authors:  Shweta Kumari; Akhilesh Kumar Verma; Sumit Rungta; Rahul Mitra; Ragini Srivastava; Narender Kumar
Journal:  ISRN Biochem       Date:  2013-10-29

5.  Effect of Di(2-ethylhexyl)phthalate on Helicobacter pylori-Induced Apoptosis in AGS Cells.

Authors:  Chuang-Hao Lin; Chien-Yi Wu; Hwang-Shang Kou; Chiao-Yun Chen; Meng-Chuan Huang; Huang-Ming Hu; Meng-Chieh Wu; Chien-Yu Lu; Deng-Chyang Wu; Ming-Tsang Wu; Fu-Chen Kuo
Journal:  Gastroenterol Res Pract       Date:  2013-12-16       Impact factor: 2.260

6.  Analysis of Patients with Helicobacter pylori Infection and the Subsequent Risk of Developing Osteoporosis after Eradication Therapy: A Nationwide Population-Based Cohort Study.

Authors:  Hong-Mo Shih; Tai-Yi Hsu; Chih-Yu Chen; Cheng-Li Lin; Chia-Hung Kao; Chao-Hsien Chen; Tse-Yen Yang; Wei-Kung Chen
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.